Up to $100 no ALK+ per Aus and Sept PBS listed Feb Crizotinib Xalkori® 14 Yes small cell 29 month no funding no funding NZ 2013 July 2015 2015 no lung cancer for funding fees Metastatic outside no Aus and melanoma; Aug no Dafrafenib Rafinlar® 11 Yes 102 None funding no funding NZ BRAF V600 2013 July registration restrictions mutant 2013 Not listed outside Aus and Sept May Denosumab Xgeva® 4 Yes refractory 6 None for this funding no funding no funding NZ 2011 2012 skeletal indication restrictions metastases no no Metastatic Aus and July July registration May Enzatulamide Xtandi® 4 Yes prostate 6 None no funding NZ 2014 2014 no 2015 no cancer listed Dec funding funding 2014 Listed for No outside no No Aug metastatic no Eribulin Halaven® Aus 1 No 0 funding no funding response 2012 breast registration restrictions cancer
registration Crizotinib Xalkori® Aus and NZ 14 Yes ALK+ cell lung cancer 29 Up to $100 per month for fees Sept 2013 PBS listed July 2015 no funding Feb 2015 no funding no no funding Dafrafenib Rafinlar® Aus and NZ 11 Yes Metastatic melanoma; BRAF V600 mutant 102 None Aug 2013 July 2013 outside funding restrictions no no funding no registration Denosumab Xgeva® Aus and NZ 4 Yes refractory skeletal metastases 6 None Sept 2011 Not listed for this indication outside funding restrictions May 2012 no funding no funding Enzatulamide Xtandi® Aus and NZ 4 Yes Metastatic prostate cancer 6 None July 2014 July 2014 listed Dec 2014 no no funding May 2015 no funding no no funding Eribulin Halaven® Aus 1 No No response 0 No Aug 2012 Listed for metastatic breast cancer outside funding restrictions no no funding no registration small
1-s2.0-S0168851017303457-mmc1.docx